# 持續進行的開放標籤ADVANCED-2研究A組更新結果於2026年美國泌尿學會年會海報發表。

*biotech · news · 2026-05-15 · Benzinga*

## Key points

- TARA-002在ADVANCED-2中於BCG初治非肌肉侵犯性膀胱癌患者達成72.4%完全緩解率。
- 12個月時，55%的可評估患者在TARA-002治療後維持完全緩解。
- 未發生3級或以上治療相關不良事件；大多為1級且短暫。
- Protara計劃於2026年底啟動ADVANCED-3註冊研究，對抗膀胱內化療。

The updated findings from Cohort A of the ongoing open-label ADVANCED-2 study were presented during a poster session at the American Urological Association 2026 Annual Meeting. • Protara Therapeutics stock is feeling bearish pressure. What’s weighing on TARA shares? Durable Responses Observed At 12 Months The dataset included 31 BCG-naïve NMIBC patients, with 29 evaluable for efficacy as of the April 5, 2026, data cutoff. The company said the complete response (CR) rate at any time reached 72.4%, with 21 of 29 patients responding to treatment. At six months, the CR rate stood at 66.7% among 27 evaluable patients. At 12 months, 55% of 20 evaluable patients maintained a complete response. Among responders, the Kaplan-Meier estimated probability of maintaining a CR for six months was 73.1%, with a 95% confidence interval of 52.9 to 93.4. The company also noted that 91.7% of patients maintained their complete response from nine months through 12 months. In addition, four of six re-induced patients achieved a complete response at six months. Investigators Highlight Safety Profile Mark Tyson, professor of urology at Mayo Clinic Phoenix and an investigator in the ADVANCED-2 study, said the data demonstrated strong durability and a favorable safety profile for TARA-002 in BCG-naïve NMIBC patients. Tyson added that the bladder cancer community continues to need effective bladder-sparing treatment options, while also pointing to the therapy's streamlined administration process for physicians and patients. According to the company, most treatment-related adverse events were Grade 1 and transient. No Grade 3 or higher treatment-related adverse events were reported, and no patients discontinued treatment because of side effects. The most commonly reported treatment-related adverse events included dysuria, fatigue and hematuria. Protara Eyes Registrational Study Expansion Jesse Shefferman, CEO of Protara Therapeutics, said the latest results reinforced the company's belief in TARA-002's potential in BCG-naïve NMIBC. Shefferman added that Protara plans to complete enrollment in the registrational BCG-unresponsive cohort of ADVANCED-2 and expects to initiate ADVANCED-3, a registrational study comparing TARA-002 with intravesical chemotherapy, in the second half of 2026. TARA Price Action: Protara Therapeutics shares were down 3.77% at $5.09 at the time of publication on Friday, according to Benzinga Pro. Over the past month, TARA has declined about 1.92% versus a 6.3% rise in the S&P 500 and is down roughly 4% year-to-date compared to the index’s 7.8% gain. Photo by e-crow via Shutterstock

**Companies:** Protara Therapeutics

[Read the full story on Benzinga](https://www.benzinga.com/news/health-care/26/05/52603756/protara-therapeutics-reports-55-complete-response-rate-in-bladder-cancer-study)

---

Canonical: https://newsio.io/zh-TW/n/95deced8-ff11-4a50-b513-5fb5fc7cfa6f/advanced-2a202612
Summarized by Newsio from Benzinga. https://newsio.io/how-it-works